Bank of New York Mellon
HARP

Bank of New York Mellon’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Bank of New York Mellon’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,927
Closed -$245K – 4736
2022
Q1 		$245K Buy
4,927
+34
+0.7% +$1.76K ﹤0.01% 4134
2021
Q4 		$369K Buy
4,893
+105
+2% +$7.17K ﹤0.01% 3975
2021
Q3 		$378K Buy
4,788
+149
+3% +$15K ﹤0.01% 3952
2021
Q2 		$644K Buy
4,639
+576
+14% +$110K ﹤0.01% 3649
2021
Q1 		$850K Buy
4,063
+594
+17% +$119K ﹤0.01% 3424
2020
Q4 		$575K Buy
3,469
+371
+12% +$57.3K ﹤0.01% 3550
2020
Q3 		$527K Sell
3,098
-17
-0.5% -$2.45K ﹤0.01% 3463
2020
Q2 		$517K Buy
3,115
+791
+34% +$123K ﹤0.01% 3451
2020
Q1 		$270K Buy
2,324
+10
+0.4% +$1.41K ﹤0.01% 3646
2019
Q4 		$343K Buy
2,314
+438
+23% +$66.4K ﹤0.01% 3749
2019
Q3 		$257K Buy
+1,876
New +$264K ﹤0.01% 3830

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon's HARP Position: Q2 2022 in Review

Bank of New York Mellon sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 4,927 shares — an estimated $245K sold.

Bank of New York Mellon first reported a position in HARP in Q3 2019 and held it in 11 quarters. The position peaked at $850K in Q1 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Bank of New York Mellon reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 4,927 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $245K.
  • Bank of New York Mellon first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Bank of New York Mellon's Harpoon Therapeutics, Inc. Common Stock position peaked at $850K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.